Appropriateness of hysterectomies at the time of surgical removal of presumed benign adnexal masses.
appropriateness of hysterectomies
hysterectomy
indications for hysterectomy
ovarian neoplasms
uterus
Journal
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
ISSN: 1879-3479
Titre abrégé: Int J Gynaecol Obstet
Pays: United States
ID NLM: 0210174
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
revised:
20
10
2021
received:
04
07
2021
accepted:
20
01
2022
pubmed:
23
1
2022
medline:
16
9
2022
entrez:
22
1
2022
Statut:
ppublish
Résumé
To evaluate factors that affect a gynecologist's decision to remove an asymptomatic uterus at the time of removal of a presumed benign adnexal mass. Retrospective chart review of hysterectomies conducted when removing presumed benign adnexal masses at a tertiary-care academic center. Primary outcome was the final pathology of the adnexal mass to determine whether the hysterectomy was medically indicated. Secondary outcomes included the rate of postoperative complications. We included 185 out of 1415 charts. Most hysterectomies were performed by gynecologic oncologists (68.8%); 113 (61%) had a frozen section and of those, 76 (67.3%) were benign. Final adnexal pathology was benign in 135 (73%) cases. Using a bivariate analysis, menopausal status (P = 0.019), parity (P = 0.047), sonographic appearance of the mass (P = 0.049), and the physician's preoperative suspicion for malignancy (P < 0.001) were significantly associated with the final adnexal pathology. At the multivariate level, only the physician's suspicion for malignancy was significantly associated with the final adnexal pathology (P < 0.0001) with an odds ratio of 7.28 (95% confidence interval 3.11-17.02). Despite gynecologists' capacity to predict the malignant nature of an adnexal mass, 135 of 185 (73%) hysterectomies were performed without a clear medical indication, at the time of removal of benign adnexal masses.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
122-128Informations de copyright
© 2022 International Federation of Gynecology and Obstetrics.
Références
Cure N, Robson SJ. Changes in hysterectomy route and adnexal removal for benign disease in Australia 2001-2015: a National Population-Based Study. Minim Invasive Surg. 2018;2018:5828071. doi:10.1155/2018/5828071
Vikstedt T, Arffman M, Heliövaara-Peippo S, Manderbacka K, Reissell E, Keskimäki I. Change in medical practice over time? A register based study of regional trends in hysterectomy in Finland in 2001-2018. BMC Womens Health. 2021;21(1):242. doi:10.1186/s12905-021-01386-2
Lepka P, Jędryka M, Misiek M, Matkowski R. Hysterectomy in Poland between 2011 and 2016 changing trends in the surgical approach to hysterectomy. Ginekol Pol. 2018;89(10):529-535. doi:10.5603/GP.a2018.0090
Simms KT, Yuill S, Killen J, et al. Historical and projected hysterectomy rates in the USA: implications for future observed cervical cancer rates and evaluating prevention interventions. Gynecol Oncol. 2020;158(3):710-718. doi:10.1016/j.ygyno.2020.05.030
Bernstein SJ, McGlynn EA, Siu AL, et al. The appropriateness of hysterectomy. A comparison of care in seven health plans. Health maintenance organization quality of care consortium. JAMA. 1993;269(18):2398-2402. doi:10.1001/jama.269.18.2398
Broder MS, Kanouse DE, Mittman BS, Bernstein SJ. The appropriateness of recommendations for hysterectomy. Obstet Gynecol. 2000;95(2):199-205. doi:10.1016/s0029-7844(99)00519-0
American College of Obstetricians and Gynecologists. 2020. Hysterectomy. [ACOG website]. Accessed August 20, 2020. https://www.acog.org/patient-resources/faqs/special-procedures/hysterectomy
Wright JD, Herzog TJ, Tsui J, et al. Nationwide trends in the performance of inpatient hysterectomy in the United States. Obstet Gynecol. 2013;122(2 Pt 1):233-241. doi:10.1097/AOG.0b013e318299a6cf
Gupta KK, Gupta VK, Naumann RW. Ovarian cancer: screening and future directions. Int J Gynecol Cancer. 2019;29(1):195-200. doi:10.1136/ijgc-2018-000016
Cancer of the Endometrium - Cancer Stat Facts. SEER. Accessed May 20, 2021. https://seer.cancer.gov/statfacts/html/corp.html
Edey KA, Rundle S, Hickey M. Hormone replacement therapy for women previously treated for endometrial cancer. Cochrane Database Syst Rev. 2018;5(5):CD008830.
Rahkola-Soisalo P, Brummer T, Jalkanen J, et al. Hysterectomy provides benefit in health-related quality of life: a 10-year follow-up study. J Minim Invasive Gynecol. 2020;27(4):868-874. doi:10.1016/j.jmig.2019.08.009
Taipale K, Leminen A, Räsänen P, et al. Costs and health-related quality of life effects of hysterectomy in patients with benign uterine disorders. Acta Obstet Gynecol Scand. 2009;88(12):1402-1410. doi:10.3109/00016340903317990
Wallace, S.K., Fazzari, M. J., Chen, H. et al. Outcomes and postoperative complications after hysterectomies performed for benign compared with malignant indications. Obstetr Gynecol. 2016;128(3):467-475. doi:10.1097/AOG.0000000000001591
Altman D, Falconer C, Cnattingius S, et al. Pelvic organ prolapse surgery following hysterectomy for benign indications. Am J Obstet Gynecol. 2008;198:572-572.e6.
Altman D, Granath F, Cnattingius S, et al. Hysterectomy and risk of stress-urinary-incontinence surgery: nationwide cohort study. Lancet. 2007;370:1494-1499.
Kaijser J, Bourne T, Valentin L, et al. Improving strategies for diagnosing ovarian cancer: a summary of the international ovarian tumor analysis (IOTA) studies. Ultrasound Obstet Gynecol. 2013;41(1):9-20. doi:10.1002/uog.12323
Jeong SY, Park BK, Lee YY, Kim TJ. Validation of IOTA-ADNEX model in discriminating characteristics of adnexal masses: a comparison with subjective assessment. J Clin Med. 2020;9(6):2010. Published 2020 Jun 26. doi:10.3390/jcm9062010
Guo W, Zou X, Xu H, et al. The diagnostic performance of the gynecologic imaging reporting and data system (GI-RADS) in adnexal masses. Ann Transl Med. 2021;9(5):398. doi:10.21037/atm-20-5170
May T, Oza A. Conservative management of adnexal masses. Lancet Oncol. 2019;20(3):326-327. doi:10.1016/S1470-2045(18)30939-2
Phinyo P, Patumanond J, Saenrungmuaeng P, et al. Diagnostic added-value of serum CA-125 on the IOTA simple rules and derivation of practical combined prediction models (IOTA SR X CA-125). Diagnostics (Basel). 2021;11(2):173. doi:10.3390/diagnostics11020173
Bottoni P, Scatena R. The role of CA 125 as tumor marker: biochemical and clinical aspects. Adv Exp Med Biol. 2015;867:229-244. doi:10.1007/978-94-017-7215-0_14
Myers ER, Bastian LA, Havrilesky LJ. Management of adnexal mass. Evid Rep Technol Assess (Full Rep). 2006;(130):1-145.
Subbian A, Devi UK, Bafna UD. Accuracy rate of frozen section studies in ovarian cancers: a regional cancer institute experience. Indian J Cancer. 2013;50:302-305.
Ratnavelu ND, Brown AP, Mallett S, et al. Intraoperative frozen section analysis for the diagnosis of early stage ovarian cancer in suspicious pelvic masses. Cochrane Database Syst Rev 2016;3(3):CD010360. Published 2016 Mar 1. doi:10.1002/14651858.CD010360.pub2